Complex preparation for treatment of acute and chronic otites of parasitary, bacterial and fungical origin in dogs, cats, fur-bearing animals and rabbits

FIELD: veterinary science.

SUBSTANCE: this invention relates to veterinary medicine and can be used in the treatment of acute and chronic otitis of parasitic, bacterial and fungal origin in dogs, cats, fur-bearing animals and rabbits. Complex preparation in the form of eardrops contains levofloxacin, clotrimazole, dexamethasone, moxidectin, and also targeted additives.

EFFECT: invention provides 100 % therapeutic efficacy for parasitizing of ear mites and 98–100 % efficacy for otites of bacterial and/or fungal etiology.

1 cl, 4 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for treating demodecosis contains metronidazole, tea tree oil, polymer carrier specified in: macrogol 400, macrogol 1,500, macrogol 4,000, and distilled water in certain amounts.

EFFECT: composition treats demodecois effectively, with no side effects.

6 cl, 8 ex

FIELD: veterinary medicine.

SUBSTANCE: method of production of water-soluble polymer anthelmintic preparations from water-insoluble substances is characterised in that the anthelmintic substance and polyvinylpyrrolidone with a low molecular weight with Mw of 12700±2700 in gram equivalent ratio of 70:30 is taken and stirred thoroughly under draft in a mortar or in a chemical reactor with a mixer of any type for 10-30 minutes, adding gradually to the mixture 40-70 parts by weight of acetone or ethyl alcohol per 100 parts by weight of the mixture of polyvinylpyrrolidone and anthelmintic substance, the obtained homogeneous mass is dried and milled to form the powder with 70% of particle size less than 5-9 mcm.

EFFECT: invention provides obtaining of complex chemical polymer anthelmintic preparations in which the unsubstituted therapeutically active groups of anthelmintic substances are maintained, at that the preparations acquire solubility in water, their bioavailability is increased, the therapeutic activity of anthelmintic is retained at 2-3-fold lower doses.

7 tbl, 8 ex

FIELD: veterinary medicine.

SUBSTANCE: agent comprises ivermectin, vitamin E, and organic solvents. The organic solvents are used as triethylene glycol and isopropyl alcohol. The components are contained in the following ratio, in wt %: ivermectin - 0.90-1.05, vitamin E - 0.01-0.02, isopropyl alcohol - 7.90-15.80, and 98% triethylene glycol up to 100.

EFFECT: invention enables to improve the efficiency of prevention and treatment of parasitic diseases of farm animals by reducing the toxic action, elimination of immunosuppression and adverse side effects while increasing antiparasitic activity of the agent, with the possibility of applying to lactating animals and use of meat without restrictions.

10 tbl, 14 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to novel 1-ω-aryloxyalkyl- and benzyl-substituted 2-iminobenzimidazolines and pharmacologically acceptable salts thereof of general formula 1 , where R = CH=CH2, R1 = 2-ClC6H4OCH2 (1b); R = CH=CH2, R1 = 4-ClC6H4OCH2 (1c); R = CH=CH2, R1 = 4-BrC6H4OCH2 (1d); R = CH=CH2, R1 = 2,4-Cl2C6H3OCH2 (1e); R = CH=CH2, R1 = 3,4-Cl2C6H3 (1f); R = CH=CH2, R1 = 4-FC6H4OCH2CH2 (1g); R = CH2N(C2H5)2, R1 = 4-C(CH3)3C6H4OCH2 (1h); R = CH2N(C2H5)2, R1 = 3,4-Cl2C6H3 (1i); R = R1 = 4-OCH3C6H4OCH2 (1j); R = 4-BrC6H4, R1 = 4-OCH3C6H4OCH2 (1k); R = 4-BrC6H4, R1 =2-OCH3C6H4OCH2 (1l); R = 4-NO2C6H4, R1 = 4-OCH3C6H4OCH2 (1m); R = 3,4-Cl2C6H3, R1 = 2-OCH3C6H4OCH2 (1n); R = 3,4-Cl2C6H3, R1 = 4-OCH3C6H4OCH2 (1o); R = C6H5OCH2, R1 = 4-OCH3C6H4OCH2 (1p); R = 2-CH3C6H4OCH2, R1 = 2-OCH3C6H4OCH2 (1q); R = 4-CH3C6H4OCH2, R1 = 2-OCH3C6H4OCH2 (1r); R = 4-C(CH3)3C6H4OCH2, R1 = 2-OCH3C6H4OCH2 (1s); R = 2-OCH3C6H4OCH2, R1 = 4-BrC6H4OCH2 (1t), having anti-protist and antibacterial activity.

EFFECT: obtaining novel compounds with useful biological activity.

1 tbl

FIELD: chemistry.

SUBSTANCE: present invention relates to an agent, having antibacterial and anti-protist activity, based on a hydrochloride of formula (1a-k) , where R=C6H5OCH2 (a); 4-CH3C6H4OCH2 (b); 4-OCH3C6H4OCH2 (c); 2-OCH3C6H4OCH2 (d); 4-FC6H4OCH2 (e); 2-ClC6H4OCH2 (f); C10H7OCH2 (g); 2,4-Cl2C6H3OCH2 (h); 4-BrC6H4OCH2 (i); 2-FC6H4 (j); 2-ClC6H4 (k).

EFFECT: obtaining a novel agent, having antibacterial and anti-protist activity, particularly with respect to Staphylococcus aureus and Escherichia coli bacteria, and moderate anti-protist activity with respect to elementary Colpoda steinii.

1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to a method for protection of the animals against fleas. The protection of animals against fleas is ensured by the oral or enteral administration of a compound of formula 1, its N-oxide or salt, in a pesticide effective amount having an anti-fleas effect during 48 hours after the oral or enteral administration into the animal.

EFFECT: using the method enables the effective protection of a mammal against fleas.

9 cl, 6 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: ameterm diclosurile is added to feed of chickens at a dose of 500 g per 1 ton of feed for 37-39 days from 8-10 days of age. After that until the end of the rearing period salinovet granules or maduvet granules are added in the feed of chickens at a dose of 500 g per 1 ton of feed.

EFFECT: method is highly effective in prevention of coccidiosis of broiler chickens, it enables to improve their livability and increase average daily weight gain at their rearing.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and is intended for prevention of coccidiosis in broiler chickens. Salinovet granulate in dose 500 g per 1 ton of forage is added to forage of broiler chickens from 8-10 day of age for 37-39 days. After that, aymeterm diklazuril in dose 500 g per 1 ton of forage is added in chicken forage for 27-29 days. Then, maduvate granulate in dose 500 g per 1 ton of forage is added to broiler chicken forage to the end of growing period.

EFFECT: method is highly efficient in prevention of coccidiosis in broiler chickens, makes it possible to increase their safety and average daily weight gain.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy and cardiology, and concerns treating cardiac valve disease of a chlamydial aethiology. That is ensured by the laboratory retest for chlamydia following the course of common anti-chlamydia therapy. If the laboratory retest shows the presence of infection, an additional session of chemotherapy is required by introducing the preparation macmiror 400 mg. The preparation is taken according to the schedule: 2 tablets in the morning at 8 am and in the evening at 8 pm for 10-12 days, with a 15-day pause; then taken for 10-12 days with another 15-day pause, and another 10-12 days of taking the tablets.

EFFECT: method provides the effective treatment of cardiac valve disease of a chlamydial aethiology ensured by eliminating an aethiological factor of the disease.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, and can be used in surgical treatment of patients with multilocular echonococcosis of liver. For this purpose transcutaneous drainage of cyst with further aspiration of its content is performed. After that, scolicide preparation is introduced. As scolicide preparation with 3-minute exposure 1% introduced is water solution of sodium hypochlorite in volume equal 1/3 of volume of aspirated liquid. After that, cyst content is re-aspirated. Procedure is repeated until "pure" aspirated liquid is obtained three times.

EFFECT: method makes it possible to ensure adequate and least traumatic treatment of said pathology without application of X-ray control due to application of definite sequence of techniques, as well as use of scolicide preparation, destroying envelopes of daughter echinococcal cysts.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical composition, containing compound of formula or for prevention or treatment of diseases, associated with oxidative stress, selected from group, consisting of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke episodes), MERRF syndrome (myoclonic epilepsy with ragged red fibres) or Kearns-Sayre syndrome, arrhythmia, cardioplegia or myocardium infarction. in formula (1) na stands for 1 or 2, Aa represents 5-membered heteroaryl or heterocycle, each of which has 2 heteroatoms, selected from N, O and S, Rla represents R5a-Xa-Ba-X′a-, Ba represents direct bond, Xa and X′a independently on each other represent direct bond or -OC(O)-, R5a represents hydrogen or 6-9-membered monocyclic or condensed cyclic heterocycle or heteroaryl, each of which has from 1 to 3 heteroatoms, selected from N, O and S, and is optionally substituted with oxo or C1-C6-alkyl, R2a represents -(CR8aR9a)pa-Ya-R7a, pa stands for number from 0 or 1, Ya represents direct bond or -O-, R7a represents hydrogen or phenyl, R3a, R8a, R9a, R10a represent hydrogen, R4a represents -(CH2)pa-Da-R10a-, Da represents C5-cycloalkyl or 6-membered heterocycle, which has 1 heteroatom, selected from N, S and O. Radical values for formula (2) are give in invention formula.

EFFECT: obtaining compositions for prevention or treatment of diseases, associated with oxidative stress.

19 dwg, 5 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula A-I, where G1 stands for hydrogen atom or R'; G2 stands for halogen atom, CN, CF3, isopropyl or phenyl, where said isopropyl or phenyl is optionally substituted with up to three substituents, independently selected from WRW; G3 stands for isopropyl or (C3-C10)cycloaliphatic ring, where said G3 is optionally substituted with up to three substituents, independently selected from WRW; W stands for bond or (C1-C6)alkylidene chain, where up to two methylene groups of W residue are optionally and independently substituted for -CO2- or -O-; RW stands for R'; and R' is independently selected from hydrogen atom or (C1-C8)alkyl group. Invention also relates to method of obtaining compound of formula FF (stands for bromine atom, fluorine atom or tret-butyl; G3 stands for tret-butyl) by hydrogenation of respective nitrocompound in presence of palladium catalyst and to methods of obtaining C-9 and 433 compounds, which include stage of hydrogenation of respective nitrocompound in presence of palladium catalyst as intermediate stage.

EFFECT: formula A-I compounds, which are intermediate for synthesis of modulators of ATP-binding cassette ("ABC") transporters.

35 cl, 4 tbl, 80 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates for composition for treatment or prevention of disorders, associated with reduced level of defensins. Composition contains from 0.005 to 1000 mg of Lactobacillus johnsonii Lal (NCC533, No CNCM 1-1225) per a daily dose, with at least 90% of L. johnsonii Lal (NCC533, No CNCM 1-1225) being transferred into state in which they become non-replicating at temperature110-140°C for 5-30 s.

EFFECT: invention provides enhancement of expression of defensin hBD1 mRNA.

5 cl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of pharmaceutics and medicine and deals with composition, possessing property to stimulate antimicrobial defence by increasing expression of endogenous β-defensins, containing strain B. longum NCC 2705, depositary number CNCM 1-2618, with said strain being brought, at least, partially into non-replicable condition by thermal inactivation, processing , at least, about 70°C. Method of stimulating endogenous antimicrobial activity of mammal by increasing expression of endogenous β-defensins, includes introduction of claimed composition.

EFFECT: group of inventions provides increase of efficiency in comparison with live strains.

12 cl, 2 dwg

FIELD: chemistry.

SUBSTANCE: group of inventions relates to biotechnology. Claimed is a strain of Bacillus subtilis Maseca-1, producing a peptide, which has the antimicrobial activity against Micrococcus luteus, Bacillus cereus and Aspergillus flavus. The strain is deposited in ATCC under number PTA-8831. The strain was isolated from pericarp of nixtamalised corn. Also claimed is a method of inhibiting Micrococcus luteus, Bacillus cereus and Aspergillus flavus in a material, containing or subjected to the action of the said microorganisms. The method includes the impact of an effective quantity of the said strain on the material.

EFFECT: group of inventions provides the effective inhibition of the growth of pathogenic microorganisms Micrococcus luteus, Bacillus cereus and Aspergillus flavus.

5 cl, 13 dwg, 7 tbl

FIELD: chemistry.

SUBSTANCE: method includes treating crushed Echinacea purpurea (L.) Moench roots and rhizome with steam, extraction with ethyl alcohol, then steeping, stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench roots and rhizome, after draining a portion of the extract, adding ethyl alcohol to the treated material, draining the whole extract; extracting crushed Echinacea purpurea (L.) Moench herbs with ethyl alcohol, steeping, then stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench herbs, after draining a portion of the extract, adding ethyl alcohol to the treated herbs, draining the whole extract; all obtained extracts are mixed, cooled and filtered under certain conditions. An Echinacea purpurea (L.) Moench tincture. Use of the method to obtain an Echinacea purpurea (L.) Moench tincture.

EFFECT: method preserves the biological activity of components of the tincture and medicinal properties.

3 cl

FIELD: biotechnologies.

SUBSTANCE: method of obtaining of a complex of antimicrobic peptides of an insect includes infecting of adipose body of an insect at a larval instar with Micrococcus luteus A270 and Escherichia coli D31 bacteria with the subsequent extraction of adipose body of an insect at a larval instar. The adipose body of an insect is placed into a nutrient medium containing water solution of sugars, inorganic salts and the antibiotic meropenem in pre-set ratio and incubated during a day with the subsequent elution of the complex of antimicrobic peptides of an insect from cultural liquid by the method of reverse-phase chromatography on the column Vydac C18 at the linear gradient of acetonitrile from 0% up to 50%.

EFFECT: invention allows to simplify a method of obtaining antimicrobic peptides.

5 dwg, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to the field of obtaining 5,9-eicosadienoic acid of formula (1), demonstrating an inhibiting effect on human topoisomerase (5Z,9Z)-5,9- The essence of the method consists in the following: tetrahydropyran ether of 5,6-heptadien-1-ol (4) and 1,2-tridecadiene (5) interact with the Grignard reagent RMgX (R=Me, Et, Pr, Bu, Oct; X=Cl, Br, I) in diethyl ether in the presence of metal Mg (powder) and the catalyst titanocenedichloride Cp2TiCl2, with the molar ratio of (4):5): RMgX:Mg:Cp2TiCl2=10:12:(30-50):32:(0.4-0.6), in an argon atmosphere at a temperature of 0-35°C and atmospheric pressure for 6-10 h, after which the reaction mass is processed with a 5% water HCl solution with obtaining 2-[(5Z,9Z)-5,9-eicosadien-1-yloxy]tetrahydro-2H-pyrane (6), which is oxidised with the Jones reagent.

EFFECT: eicosadienic acid is promising as the medication, possessing anti-tumour, antiviral and antibacterial action.

2 cl, 1 tbl, 1 dwg, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula , wherein A and V independently represents H or a halogen; Q is absent; R4 independently represents H, a C1-C6 alkyl or C3-C6 cycloalkyl; R7 represents H; and R8 represents a C1-C10 alkyl substituted by OH or C1-C6 alkoxy; or C1-4 alkyl substituted by a 5-6-merous aromatic heterocyclic ring containing 1-2 heteroatoms specified in N and S, wherein the above aromatic heterocyclic ring is optionally substituted by a C1-C10 alkyl; or in -NR7R8, R7 and R8 together with N can form an optionally substituted azacyclic ring containing where applicable an additional heteroatom specified in H, O and S, as a cycle member, optionally substituted by a C1-C10 alkyl, which is substituted by a C1-C6 alkoxy; m is equal to 0; n is equal to 0. The invention also refers to a compound of formula (wherein the substitutes are those as specified in the patient claim), to a pharmaceutical composition containing a therapeutically effective amount of the compounds of formula (VIII), and to a method of treating or relieving a cell-proliferative disorder.

EFFECT: compound of formula (VIII) inhibiting cell proliferation or cell apoptosis.

12 cl, 1 dwg, 14 tbl, 55 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to the strain Lactobacillus rhamnosus CNCM I-3690 and to a dairy food product containing the above strain. The presented strain possesses the mannose-specific adhesive properties. The strain possesses the antimicrobial properties in relation to, e.g. Escherichia coli, Salmonella enteritidis and Lysteria monocytogenes.

EFFECT: strain possesses the immunomodulatory properties, particularly possesses an ability to inhibit an inflammatory reaction of HT-29 epithelial cells.

2 cl, 2 dwg, 5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition for control of pain accompanying individual's joint diseases containing hyaluronic acid, which is cross-linked by cycling a double bond in a group of cinnamic acid in partially amidated hyaluronic acid presented by formula (1) to form a cyclobutane cycle, wherein in the above formula, Ar represents a phenyl group, n is equal to an integer 2 or 3; HA represents a carboxy residue of hyaluronic acid, and m represents a relation of amidation of hyaluronic acid to all the carboxyl groups and is equal to 3-50% in relation to all the carboxyl groups, and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition represents a product for injection, wherein the pharmaceutical composition represents the product for injection, wherein the amount of the cross-linked hyaluronic acid makes 1 wt % at the total amount of the product for injection, wherein a single dose of the product for injection makes 2-3 ml, wherein the pharmaceutical composition represents a single-use preparation, which is administered every 13 weeks and more.

EFFECT: invention provides the extremely long analgesic action after the single administration, earlier onset of the analgesic action.

15 cl, 1 dwg, 5 tbl, 1 ex

Up!